1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 May 2024
Admin
News Article

Soleno Therapeutics Secures BTD for DCCR Extended-Release Tablets

Soleno Therapeutics Secures FDA Breakthrough Therapy Designation for DCCR Extended-Release Tablets Targeting Prader-Willi Syndrome (PWS)

Overview

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO) has announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to diazoxide choline for the treatment of adults and children aged 4 years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia. This designation acknowledges the FDA's assessment of preliminary data from the Phase 3 clinical development program, suggesting that diazoxide choline may offer significant improvement over existing therapies on clinically significant endpoints.

A Significant Milestone

Soleno Therapeutics, noted that this designation is a significant milestone for their DCCR clinical development program, emphasizing the seriousness of PWS as a condition and the potential of DCCR to be an effective treatment.
The focus remains on preparing the New Drug Application (NDA) submission for DCCR in PWS, expected in mid-2024.

BTD

The Breakthrough Therapy Designation from the FDA accelerates the development and review of drugs for serious conditions. It involves intensive guidance and organizational commitment, potentially leading to priority review and other actions to expedite the process.

Diazoxide Choline Status

Diazoxide choline has Orphan Drug Designation for PWS in both the U.S. and E.U., as well as Fast Track Designation in the U.S.

Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) affects approximately one in every 15,000 live births, characterized by hyperphagia, a chronic and life-threatening hunger. Current therapies do not effectively address the core symptoms of PWS.

DCCR Tablets

DCCR (Diazoxide Choline) Extended-Release Tablets offer a novel once-daily formulation.
Supported by extensive clinical data, including Phase 1 and Phase 2 studies, DCCR has shown promise in addressing hyperphagia and other symptoms associated with PWS.
With multiple regulatory designations, including Orphan Drug, Fast Track, and Breakthrough Therapy, DCCR holds considerable potential as a therapeutic option for PWS patients.